Follow the 휴메딕스 share price and the full insider trade history of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 휴메딕스 has published 29 insider filings. Market capitalisation: €272.6bn. The latest transaction was reported on 16 March 2026 (Other). Among the most active insiders: 배준규. Every trade is free.
29
Insider Decl.
n/a
Thresholds
n/a
9 ops.
Buy Volume
n/a
4 ops.
Sell Volume
8Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 469 of 27,949 companies
84.9
score / 100
Value
93
Quality
77
FCF yld14%
Earn yld19%
EV/EBITDA3.7x
ROE7.3%
Gross mgn47%
Net mgn30%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Humedics is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development of innovative medical products.